{"entry":[{"category":[{"coding":[{"display":"REG536"}],"text":"Regulation Code"}],"condition":[{"coding":[{"display":"Locally-Advanced or Metastatic breast cancer (MBC)"}],"text":"Disease Condition"},{"coding":[{"code":"10070575","display":"MedDRA","system":"http://terminology.hl7.org/CodeSystem/mdr","version":"2.0.1"},{"code":"10065430","display":"MedDRA","system":"http://terminology.hl7.org/CodeSystem/mdr","version":"2.0.1"}],"text":"MedDRA Condition"}],"contact":[{"name":"Head of EU, Trial Information Support Line-TISL, Switzerland","telecom":[{"system":"phone","use":"work","value":"0041616881111"},{"system":"email","use":"work","value":"global.rochegenentechtrials@roche.com"}]}],"contained":[{"actual":true,"characteristic":[{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueCodeableConcept":{"coding":[{"code":"male","display":"Male","system":"http://hl7.org/fhir/administrative-gender","version":"5.0.0"},{"code":"female","display":"Female","system":"http://hl7.org/fhir/administrative-gender","version":"5.0.0"}],"text":"Genders"}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueCodeableConcept":{"coding":[{"display":"65+ years"},{"display":"18-64 years"}],"text":"Age range"}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueCodeableConcept":{"coding":[{"display":"21"}],"text":"Study Size"}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueCodeableConcept":{"coding":[{"display":"Donn√©es non disponible"}],"text":"Study Category"}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueCodeableConcept":{"coding":[{"display":"Women of child bearing potential not using contraception, Women of child bearing potential using contraception"}],"text":"Study Population"}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueCodeableConcept":{"coding":[{"display":"INDISPONIBLE"}],"text":"Study Inclusion"}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":true,"valueCodeableConcept":{"coding":[{"display":"INDISPONIBLE"}],"text":"Study Exclusion"}}],"id":"2022-500014-26-00-enrollment-group-id","type":"person","resourceType":"Group"}],"description":"INDISPONIBLE","enrollment":[{"display":"Reference to group detailing study characteristics","reference":"#2022-500014-26-00-enrollment-group-id","type":"Group"}],"id":"2022-500014-26-00","identifier":[{"assigner":{"display":"INDISPONIBLE"},"use":"official","value":"INDISPONIBLE"},{"assigner":{"display":"euclinicaltrials.eu","reference":"https://euclinicaltrials.eu/app/#/view/2022-500014-26-00"},"use":"secondary","value":"2022-500014-26-00"}],"meta":{"lastUpdated":"2023-04-12T00:00:00.000Z"},"phase":{"coding":[{"code":"phase-3","display":"Phase 3","system":"http://terminology.hl7.org/CodeSystem/research-study-phase","version":"4.0.1"}],"text":"Therapeutic confirmatory  (Phase III)"},"status":"active","title":"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER","resourceType":"ResearchStudy"}],"link":[{"relation":"self","url":"http://localhost:3000/R4/ResearchStudy?_getpagesoffset=0"},{"relation":"next","url":"http://localhost:3000/R4/ResearchStudy?_getpagesoffset=2"}],"resourceType":"Bundle","total":1,"type":"searchset"}